Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Cytarabine; Dexamethasone; Doxorubicin liposomal; Etoposide; Rituximab; Temozolomide
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 18 Jan 2019 Planned End Date changed from 15 Jun 2022 to 15 Jun 2023.
- 17 Jan 2019 Planned End Date changed from 15 Jun 2023 to 15 Jun 2022.
- 04 Dec 2018 Results assessing the durability of CR and PFS in relapsed/refractory patients with extended follow-up, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology